Cardiomyopathy News and Research

RSS

Cardiomyopathy is a group of diseases with primary, usually diffuse, involvement of the myocardium. The myocardial disease is not secondary to ischaemic, valvular, congenital or pericardial disease.

Selenium supplements and heart disease risk: an interview with Dr Saverio Stranges, University of Warwick

Selenium is a micronutrient which has antioxidant properties by means of selenoproteins which play many important functions in the body. They actually are contained in many different foods. The amount of selenium we get from diet is closely linked to the amount of selenium in the soil.

21 Feb 2013

Steroid therapy impedes Duchenne’s cardiomyopathy

Steroid therapy is associated with a considerable reduction in all-cause mortality and new-onset and progressive cardiomyopathy in patients with the debilitating X-linked disease Duchenne muscular dystrophy.

11 Feb 2013

Researchers unveil first maturation-based ‘disease in a dish’ model for ARVD/C

Most patients with an inherited heart condition known as arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) don't know they have a problem until they're in their early 20s. The lack of symptoms at younger ages makes it very difficult for researchers to study how ARVD/C evolves or to develop treatments. A new stem cell-based technology created by 2012 Nobel Prize winner Shinya Yamanaka, M.D., Ph.D., helps solve this problem.

29 Jan 2013

Skin cells transformed into heart cells for research into cardiomyopathy

...

28 Jan 2013

FDA updates metal-on-metal hip replacement advice

The US Food and Drug Administration has updated its advice on the use of metal-on-metal hip replacement prostheses.

25 Jan 2013

Potential stem cell therapy for Duchenne’s

Researchers have found that injecting aorta-derived stem cells into the hearts of dystrophin-deficient mice prevents the onset of dilated cardiomyopathy, raising hopes of a potential new treatment approach to prevent or reverse the condition in human Duchenne muscular dystrophy.

17 Jan 2013

Top-line results from Amgen’s Aranesp Phase 3 trial on heart failure and anemia

Amgen today announced top-line results of the Phase 3 Aranesp (darbepoetin alfa) RED-HF (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial.

17 Jan 2013

Stem cell transplantation prevents decrease in heart function associated with DMD

Researchers have shown that transplanting stem cells derived from normal mouse blood vessels into the hearts of mice that model the pathology associated with Duchenne muscular dystrophy (DMD) prevents the decrease in heart function associated with DMD.

16 Jan 2013

Young humans capable of generating new heart muscle cells

Researchers at Boston Children's Hospital have found, for the first time that young humans (infants, children and adolescents) are capable of generating new heart muscle cells.

11 Jan 2013

Stanford scientists identify molecular basis for hypertrophic cardiomyopathy

When a young athlete dies unexpectedly on the basketball court or the football field, it's both shocking and tragic. Now Stanford University School of Medicine researchers have, for the first time, identified the molecular basis for a condition called hypertrophic cardiomyopathy that is the most common cause for this type of sudden cardiac death.

4 Jan 2013

AHA/ASA identify top cardiovascular and stroke research advances for 2012

Resuscitation, cell regeneration, a new high blood pressure treatment and developments in devices for treating stroke are among the key scientific findings that make up this year's top cardiovascular and stroke research identified by the American Heart Association and American Stroke Association.

18 Dec 2012

Link between CTNNA3 gene mutations and arrhythmogenic right ventricular cardiomyopathy

Unfortunately, newspaper articles about young athletes dying suddenly on the field are not unheard of. Such reports fuel discussions about compulsory screening, for example of young footballers, for heart failure. Research by scientists from Ghent (VIB/UGent) and Italy will benefit these screening methods.

12 Dec 2012

Pharmacological stress echo can identify rejected hearts suitable for transplantation

Hearts previously rejected due to donors' age or other risk factors can now be declared viable for transplantation using pharmacological stress echo, according to research presented at EUROECHO and other Imaging Modalities 2012.

5 Dec 2012

USPTO approves patent for Axiogenesis’ in vitro drug discovery assay to treat HCM

The USPTO approved a patent for Axiogenesis AG for the invention of its in vitro assay to screen pharmaceutical drug candidates for effectiveness and safety in treating Hypertrophic Cardiomyopathy (HCM).

5 Dec 2012

Young relatives of sudden cardiac death individuals at high heart disease risk

Young first- and second-degree relatives of individuals who were victims of sudden cardiac death are at a significantly increased risk for developing cardiovascular disease, research suggests.

19 Nov 2012

New €6 million European project to address complications associated with diabetes

NUI Galway has been awarded a major new €6 million European project, designed to address complications associated with diabetes. The research project will examine the ability of stem cells to safely control glucose levels and alleviate the damage caused by six different diabetic complications.

19 Nov 2012

Young relatives of sudden cardiac death individuals at high heart disease risk

Young first- and second-degree relatives of individuals who were victims of sudden cardiac death are at a significantly increased risk for developing cardiovascular disease, research suggests.

16 Nov 2012

Trastuzumab increases risk of heart failure in older women with breast cancer

Heart failure is a relatively common complication in older women with breast cancer, but the risk is even higher in those patients treated with adjuvant trastuzumab (Herceptin-), Yale School of Medicine researchers report in the current issue of the Journal of the American College of Cardiology.

15 Nov 2012

CHOP presents new findings on pediatric cardiovascular disease at AHA 2012

Physician-researchers from the Cardiac Center at The Children's Hospital of Philadelphia presented new findings on pediatric cardiovascular disease at the American Heart Association's Scientific Sessions 2012 in Los Angeles.

9 Nov 2012

Positive results from BioCardia's Helical Infusion System Phase 1/2 trial on ischemic cardiomyopathy

BioCardia, Inc., focused on regenerative biologic therapies for cardiovascular disease, today announced positive results from a Phase 1/2 heart failure trial using the Company's Helical Infusion System, comprising the Helical Infusion System Catheter and Morph Vascular Access Catheter, to deliver allogeneic, or "off-the-shelf," and autologous, or from the treated patient, mesenchymal (adult) stem cells (MSCs) via transendocardial injection.

7 Nov 2012